Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN SP versus FLUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN SP versus FLUTEX.
CORDRAN SP vs FLUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
50 mg orally once daily
None Documented
None Documented
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid